Which organization recently opposed copay accumulator and maximizer programs?

The American Society of Clinical Oncology (ASCO) is known for advocating for policies that improve patient access to cancer care and reduce financial burdens associated with treatment. Their recent opposition to copay accumulator and maximizer programs stems from the increasing financial strain these programs place on patients.

Copay accumulator programs prevent drug manufacturer copay assistance from counting toward a patient's out-of-pocket maximum, while maximizer programs increase the patient’s out-of-pocket costs by altering the way copay assistance is applied. Both programs can lead to significant financial barriers for patients seeking necessary medications, particularly in oncology, where treatment can be both complex and costly.

By opposing these practices, ASCO aims to protect patients from unpredictable and potentially prohibitive out-of-pocket costs, ensuring that access to necessary treatments is preserved. This stance is consistent with ASCO’s broader mission to advocate for high-quality care, transparency in pricing, and patient-centered policies.